Charleston Ketamine Center

MUSC Health is a comprehensive healthcare system based in Charleston, SC, offering a wide range of services, including specialized care in oncology, cardiology, and orthopedics, as well as innovative programs in creative arts therapy. With a commitment to patient-centered care, the organization prioritizes accessibility and collaboration within its statewide network of clinical affiliates and healthcare providers. In addition to advanced medical services, MUSC Health emphasizes community involvement through volunteer opportunities and educational programs. The system is recognized for its dedication to evidence-based practices and has achieved prestigious awards such as Magnet designation, reflecting its focus on nursing excellence and quality care delivery. Generated from the website

Patrick Flume is a Distinguished Professor of Medicine and Pediatrics at the Medical University of South Carolina. He serves as the Powers-Huggins Endowed Chair for Cystic Fibrosis and oversees a large Cystic Fibrosis (CF) Center, including the largest adult CF program in South Carolina. He also leads large clinical programs dedicated to patients with bronchiectasis and non-tuberculous mycobacterial (NTM) infections. He is recognized by the national and international CF community having served on the CF Foundation Center Committee, the Adult Care Consensus Committee, and the Advisory Task Force on Adult Issues, the Professional Education Committee, the European CF Society’s Best Practices committee, and as founding co-chair of the CF Foundation’s Pulmonary Practice Guidelines Committee. He co-led the International Working Group on Antimicrobial Resistance in Cystic Fibrosis. He is the Editor-in-Chief for the Journal of Cystic Fibrosis. He serves as Associate Vice President for Clinical Research at MUSC, leads a very busy clinical research program for CF, bronchiectasis, and NTM, and is co-principal investigator for the South Carolina Clinical & Translational Research Institute. Many of these studies are related to new drug and therapy development for patients, but he also has an interest in determining optimal management of CF pulmonary exacerbations and is the co-PI in the STOP trials, aimed at identifying optimal treatments for exacerbations.

Dr. Stephen Savage graduated from Dartmouth College in 1989, completed medical school at the Columbia University College of Physicians and Surgeons in 1993 and received his urology training at the Mount Sinai Medical Center in New York City in 1999. He went on to receive fellowship training in minimally invasive urology at the Cleveland Clinic Foundation. Following completion of his fellowship, he was the director of minimally invasive urology at Mount Sinai Medical Center from 2000 through 2002 when he joined the staff at Memorial Sloan Kettering Cancer Center to help develop their minimally invasive urologic oncology program. He joined the staff at the Medical University of South Carolina and Hollings Cancer Center in 2004 as an associate professor of urology and director of minimally invasive urology.Dr. Savage has interest and expertise in the minimally invasive treatment of urologic cancers including prostate, kidney, bladder and testicular. He has performed complex minimally invasive surgeries since 1999 and continues to utilize these techniques to benefit patients in the approach to urologic cancer. He has published numerous articles related to urologic cancers and participates in many multidisciplinary clinical trials. He is the vice chairman of the Department of Urology and is the director of the urologic oncology fellowship at MUSC.